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ABSTRACT
Introduction: Many resources are required to provide
postoperative care to patients who receive a cochlear
implant. The implant service commits to lifetime follow-
up. The patient commits to regular adjustment and
rehabilitation appointments in the first year and annual
follow-up appointments thereafter. Offering remote follow-
up may result in more stable hearing, reduced patient
travel expense, time and disruption, more empowered
patients, greater equality in service delivery and more
freedom to optimise the allocation of clinic resources.
Methods and analysis: This will be a two-arm
feasibility randomised controlled trial (RCT) involving 60
adults using cochlear implants with at least 6 months
device experience in a 6-month clinical trial of remote
care. This project will design, implement and evaluate a
person-centred long-term follow-up pathway for people
using cochlear implants offering a triple approach of
remote and self-monitoring, self-adjustment of device and
a personalised online support tool for home speech
recognition testing, information, self-rehabilitation, advice,
equipment training and troubleshooting. The main
outcome measure is patient activation. Secondary
outcomes are stability and quality of hearing, stability of
quality of life, clinic resources, patient and clinician
experience, and any adverse events associated with
remote care. We will examine the acceptability of remote
care to service users and clinicians, the willingness of
participants to be randomised, and attrition rates. We will
estimate numbers required to plan a fully powered RCT.
Ethics and dissemination: Ethical approval was
received from North West—Greater Manchester South
Research Ethics Committee (15/NW/0860) and the
University of Southampton Research Governance Office
(ERGO 15329).
Results: Results will be disseminated in the clinical and
scientific communities and also to the patient population
via peer-reviewed research publications both online and in
print, conference and meeting presentations, posters,
newsletter articles, website reports and social media.
Trial registration number: ISRCTN14644286;
Pre-results.
INTRODUCTION
Cochlear implants are the most successful of
all neural prostheses;1 they can provide
hearing to people with severe to profound
deafness. Approximately 1200 people receive
a cochlear implant in the UK each year.2
The total number of people with implants is
∼14 000 in the UK and 600 000 worldwide.3
Numbers are likely to increase rapidly: only
∼5% of eligible people in the UK have
received an implant,3 and the number of
people of retirement age is projected to
increase by 28% by 20354 meaning a further
increase in the number of hearing-impaired
people. Cochlear implant care in the UK is
provided at 1 of 19 tertiary centres involving
assessment, surgery, and a resource-intensive
acute phase of device adjustment and
rehabilitation. These centres may be several
hours away from the patient’s home necessi-
tating travel expense, time off work and
family disruption. Currently UK implant
centres review patients on a clinic-led
Strengths and limitations of this study
▪ This will be the first randomised controlled trial
(RCT) of a triple approach to remote care for
people using cochlear implants.
▪ No formal power calculations were performed as
this is the first study of its kind and acts as a
feasibility RCT.
▪ The generic Patient Activation Measure (PAM)
may not be sensitive enough to show change in
people with cochlear implants: a condition-
specific empowerment measure may be required.
▪ People using cochlear implants who volunteer to
take part may not be representative of the popu-
lation of people with implants.
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schedule; this means that review appointments can
occur that provide little beneﬁt to the patient.
Conversely when some patients attend a routine appoint-
ment, there is hearing deterioration which the patient
had not noticed. This is often remedied by replacing
equipment that the patient could have done at home.
Making this care pathway patient-centred instead may
provide a more efﬁcient and effective service and allow
more timely identiﬁcation of issues.
When a patient attends a long-term follow-up appoint-
ment, the following tasks may be performed: speech rec-
ognition testing, device adjustment, rehabilitation,
equipment check and troubleshooting, and provision of
replacement or upgraded equipment. We propose that
at least some of these tasks could be performed by the
patient themselves at home, and that people using coch-
lear implants should only attend the clinic when there is
clinical need (no more routine appointments). Potential
beneﬁts for the patient are:
▸ More stable hearing (problems identiﬁed and
resolved quicker);
▸ Better hearing (ability to ﬁne tune when away from
clinic);
▸ Convenience of not travelling to routine
appointments;
▸ Reduction of travel cost and time, time off work and
disruption to family life;
▸ Increased conﬁdence to manage own hearing;
▸ Greater equality in service delivery (same level of
service regardless of distance from clinic).
It may also mean that the clinic has greater resources
(time, money, space) to see complex cases and the
expanding population of new patients, although health
economics analysis will not occur in this trial. People
using cochlear implants and their families would gener-
ally like to take a more active role in their care and
welcome the use of technology to assist self-care.5 6 The
National Health Service (NHS) has a strong commit-
ment to supporting self-care for people with long-term
conditions7 with ‘the vision of a citizen-centred, digitally
enabled, health and social care system’.8 Evidence shows
a signiﬁcant improvement in outcomes when patients
use self-management tools9 and those who are activated
and involved in their care tend to have better health
outcomes.10 11
The standard clinical care pathway
Speech recognition testing
The main speech recognition measure used in UK
clinics is Bamford-Kowal-Bench (BKB) sentences12 in
quiet and noise; these are usually performed in a sound-
treated room in the clinic by experienced clinicians,
although there are some reports of testing remotely
using an assistant at a remote location and video confer-
encing facilities.13 14 Speech perception in noise testing
using digits has been developed;15 digits are highly
familiar stimuli and are usually known by people with
even basic language skills. Digit testing requires a closed
set response and thus is suitable for self-testing over the
telephone or internet16 17 and has a minimal learning
effect.18 The test correlates well with speech recognition
in noise with sentences in people using cochlear
implants.19–22 A digit test in English is freely available
online at the Action on Hearing Loss website23 and also
as an application for mobile devices (Action on Hearing
Loss Hearing Check).
Device adjustment
In order to provide beneﬁt to a hearing-impaired
person, the levels of electrical stimulation need to be
individually adjusted for soft and loud sounds on up to
22 electrode contacts in the cochlea. The levels can
change as the person using a cochlear implant
becomes more used to listening, more experienced at
doing the task and as physiological changes occur. Most
cochlear implant centres offer frequent appointments
in the ﬁrst few months following implantation and
annual adjustment appointments thereafter.24 Device
adjustment usually occurs in the clinic in a sound-
treated room, led by an experienced clinician. Several
centres are now offering remote device program-
ming.13 25–32 However, these reports continue to use a
clinician-centred model involving the patient attending
a centre closer to their home where an assistant is
present, and the cochlear implant centre clinician
leading the session using video conferencing and
remote desktop connection.
People using cochlear implants have commented that
they would like to be able to adjust their device para-
meters in their own home or work environment, rather
than just in the sound-treated clinic room.5 The
company Cochlear have introduced a self-ﬁtting para-
digm (Remote Assistant Fitting) using the speech pro-
cessor remote control that patients already have. This
allows adjustment of programming to be done by the
patient at anytime and anywhere with equivalent
hearing outcomes to audiologist-led sessions.33
Rehabilitation
Many clinical resources are devoted to rehabilitation
after people receive a cochlear implant; the new sound
can be difﬁcult to get used to. Rehabilitation appoint-
ments are frequent in the ﬁrst year and may be offered
annually thereafter.34 Computer-based auditory training
completed by the patient at home can signiﬁcantly
improve their speech recognition.35
Equipment troubleshooting/repairs/spares provision/
upgrades
Cochlear implant speech processors are complex; some
parts need regular replacement in order to keep the
device in optimum condition.36 No reminder is given on
the device. Many NHS cochlear implant centres offer an
upgraded speech processor approximately every 5 years,
requiring a clinic visit.34
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The intervention
This paper describes the protocol for a feasibility project
to design, introduce and evaluate a patient-centred
remote care approach for adults using cochlear implants
long term. This is necessary preparatory work for a fully
powered randomised controlled trial (RCT) that will be
extended across the UK. It is a prospective RCT whereby
60 patients will be randomised to either a control group
(usual clinical care) or a remote care group where they
are given access to new remote care tools. The patients
in the remote care group will monitor their hearing at
home, and some can ﬁne tune their hearing to suit
their own real-world environment. Their other needs
will be met through a personalised online support tool.
Assessment of front-line staff perceptions of remote care
will also be formally evaluated using repeated interviews
with 10 staff members at the start, midpoint and end of
the project. Empowering the patient to self-care at home
could enable better and more stable hearing and a
more convenient and accessible service.
METHODS AND ANALYSIS
Trial design
This will be a two-arm feasibility RCT involving 60 adults
with cochlear implants with at least 6 months device
experience in a 6-month clinical trial of remote care
(see ﬁgure 1 ﬂow chart). This feasibility trial will inform
a later fully powered RCT and will be used to estimate
characteristics of the outcome measures, follow-up rates,
adherence, willingness of participants to be randomised,
and the number of eligible and willing participants. The
later substantive RCT will aim to answer the question ‘Is
remote care an acceptable and effective method of
caring for adults using cochlear implants?’ using more
participants and a longer time scale.
Setting and participants
The trial will be conducted at the University of
Southampton Auditory Implant Service (USAIS): a ter-
tiary treatment centre mostly funded by NHS referrals.
The study sponsor is the University of Southampton.
The funder (The Health Foundation) and sponsor have
not contributed towards the study protocol. Some anon-
ymised data will be analysed at the University of
Nottingham. Participants will not necessarily be USAIS
patients.
Proposed sample size
No formal power calculations were performed as this is a
feasibility trial to plan a later RCT. The literature
Figure 1 Flow chart of project.
Items in blue apply to all enrolled
cochlear implant users, purple:
control group only, orange:
remote care group only, green:
staff. CIRCA, Cochlear Implant
Remote Care; HUI, Health
Utilities Index; PAM, Patient
Activation Measure; SSQ,
Speech, Spatial and Qualities of
Hearing.
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suggests sample sizes between 30 and 50 for a feasibility
trial.36 37 Sixty participants was selected (30 in each
group) in order to gather a range of different service
users’ experiences of the remote care tools and to esti-
mate the effect size on the primary outcome measure.
Recruitment
Potential participants will be sent a covering letter and
the Participant Information Sheet several weeks before
consenting. The clinical trial will begin in January 2016.
There has been much interest in the project among
people using cochlear implants in the UK, so adequate
enrolment to reach target size is not of concern.
The principal investigator (PI; HC) will access the
USAIS clinical database and contact patients who fulﬁl
the inclusion criteria, excepting those who have indi-
cated that they do not wish to receive research invita-
tions. Information will also be placed in the USAIS
waiting room.
An advertisement will be placed on the USAIS website
(http://www.AIS.southampton.ac.uk)
from the date of ethical approval to the end of recruit-
ment. A link will be tweeted from @UoS_AIS and
@CIRemoteCare once a week from study ethical
approval to end of recruitment. Details of the study will
be placed on the National Cochlear Implant Users’
Association website.
Patients from other centres may respond to the adver-
tisement; we will obtain participants’ permission to
notify individual teams if their patients are involved.
Inclusion criteria
▸ Person using cochlear implant (any device, unilateral
or bilateral) for at least 6 months.
▸ Living in the UK.
▸ Aged 18 years or more.
▸ Able to give informed consent.
▸ Sufﬁcient English to understand study documenta-
tion and participate in testing.
▸ Access to a computer or device with internet access.
Exclusion criteria
Those that do not fulﬁl the inclusion criteria plus any
medical condition or known disability that would limit
their capacity to use the online support tool.
Randomisation
Participants who consent to the study will be allocated to
the remote care pathway or the standard care pathway at
the baseline visit by the PI using minimisation soft-
ware.37 Minimisation seeks to achieve a balance across
the arms of a trial on one or more predeﬁned patient
characteristics.38 39 The minimisation will balance the
following factors:
▸ CI user less than a year or more than a year;
▸ Gender;
▸ Distance from the clinic (local or non-local, ie, within
20 miles or more than 20 miles away);
▸ Device (Cochlear or not);
▸ Ability to use Cochlear Remote Assistant Fitting (or
not).
The approach will use biased coin minimisation with a
base probability of 0.7. Imbalance between the groups
will be quantiﬁed using the marginal balance method.40
Blinding
It will not be possible to blind participants to which
group they are in. Baseline measures will be completed
before allocation. Efforts will be made to blind clinicians
to which group the participant belongs when they
perform exit measures. Where possible, blinded mea-
sures will be passed to the University of Nottingham for
analysis.
Interventions
Control group: standard clinical care pathway
Participants in the control group will continue with their
usual care pathway; they will not have access to remote
care. They will be asked to attend twice for this project:
baseline and exit measures.
Intervention group: remote care
Those randomised into the treatment group (remote
care group) will receive cochlear implant care remotely
for 6 months. Clinic appointments will be given if
required, and participants must still adhere to any
medical check-ups with the cochlear implant surgeon.
Participants may access the tools as often as they wish
(minimum twice required for project) and can use them
wherever they wish (at home, at a friend’s house, at the
library, etc). Remote care will comprise:
1. Remote and self-monitoring: Remote care trial partici-
pants will access a password-protected online
speech recognition test based on the Triple Digit
Test (TDT). The site is provided and maintained by
Action on Hearing Loss. Participants will listen to
sets of three digits in background noise and type in
the numbers they hear. Participants will be required
to do self-testing at least in months 1 and 6, but
can do it at any time during the 6 months. They
will be advised that they can do the hearing test
using a direct connection from the computer
sound card to their speech processor (with the
advantage of excluding distracting home environ-
mental noise) or they can listen via speakers (with
the advantage of testing their whole hearing system
including the microphone). Participants will be
encouraged to experiment with different processor
settings and programs and redo the test whenever
they want. Although the number of times partici-
pants take the test will be recorded, the data cap-
tured will be qualitative only: participants’
preference and experience of being able to test
their hearing at home.
2. Self-adjustment of device (Remote Assistant Fitting): Only
those people using cochlear implants with newer
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Cochlear devices (CI500 series, CI422 or CI24RE
devices using CP800 or CP900 series processors) will
be able to participate in the self-adjustment of
device; the other manufacturers do not have these
tools yet. Participants will use Remote Assistant
Fitting to adjust their device programming at any
time anywhere. Patients will be required to do self-
adjustment at least in months 1 and 6, but can do it
at any time during the 6 months.
Those patients in the trial who are eligible for a pro-
cessor upgrade will receive the upgrade at home rather
than coming into the clinic. This will apply to users of
all devices.
3. Online support tool: The research team will design a
new online support tool for adults with cochlear
implants using LifeGuide.41 LifeGuide is an open
source software platform that allows the development
and trialling of interactive web-based interventions.
This will be an iterative process incorporating feed-
back from service users at all stages, including focus
groups of adults with cochlear implants. The online
support tool (Cochlear Implant Remote Care,
CIRCA) will incorporate personalised equipment
help and information, troubleshooting, rehabilita-
tion, goal setting, help with music and telephone use,
and a method of ordering replacement equipment in
an easy format to people who may be inexperienced
internet users. It will also store the TDT speech rec-
ognition test result entered by the participant and
provide a comparison with the baseline test and
appropriate feedback (no signiﬁcant change or sig-
niﬁcantly worse: contact the centre). Participants will
be given a unique user name to log in to this support
tool; they can access it at any time. They will have the
option to include a mobile phone number if they
wish to receive reminder text messages for speech
processor maintenance and study information.
The participant will enter the following:
▸ Name they would like to be called;
▸ Email address;
▸ Main speech processor;
▸ Month and year of ﬁrst implant surgery;
▸ Date microphone cover and rechargeable batteries
were changed (if appropriate);
▸ Year of birth (optional);
▸ First part of postcode (optional);
▸ Born deaf or lost hearing (optional);
▸ Mobile phone number (optional).
Staff change management assessment
Moving to remote care represents a signiﬁcant change
to cochlear implant centre staff; feedback will be
obtained throughout from clinicians using a SharePoint
(Microsoft Corporation, Redmond, Washington, USA)
feedback site, discussions at centre meetings, the project
Steering Group and informal discussions. A formal
change evaluation will also occur. Interviews will be con-
ducted with 10 members of the multidisciplinary team at
3-month intervals over a period of 6 months (ie, 0, 3,
6 months). Capturing data near the beginning, middle
and end of the project will enable us to better capture
the ongoing and iterative relationships between percep-
tions and learning and how these change in response to
leadership, social context and decision-making processes
over time.42 Interviews will be carried out in the work
place or over the phone in accordance with the guide-
lines and codes of conduct recommended by the British
and American Psychological Societies.43 44 Repeated
interviews with the same individuals will provide insights
into how the nature and content of challenges of tele-
health implementation and acceptance are changing
and evolving as part of a dynamic process. Examining
and understanding staff responses to the change will
optimise the chance of the change being sustainable.
The following information will be collected from staff:
▸ Age (in 10-year age bands);
▸ Gender;
▸ Role in team;
▸ Number of years working in cochlear implant centre.
Staff recruitment
Ten staff members who work with adults using cochlear
implants at USAIS will be recruited. An email will be
sent to all eligible staff enclosing the Staff Participant
Information Sheet. This information will also be placed
on the staff SharePoint site. Any staff member working
at USAIS in a clinical role with adults with implants will
be eligible to take part, including staff who support
patient equipment needs. A sample size of 10 was
chosen in order to provide a variety of differing profes-
sions and viewpoints. If more than 10 people want to
take part, participants will be selected in order to
provide a balance of different clinical roles.
Outcome measures
Baseline measures
All participants will undergo the following baseline mea-
sures after signing the consent form:
▸ Speech recognition testing (BKB sentences in quiet
and noise and TDT);
▸ PAM;
▸ The Speech, Spatial and Qualities of Hearing (SSQ)
questionnaire;
▸ Quality of life questionnaire: Health Utilities Index
(HUI) mark 3.
The speech recognition testing is described under the
earlier section ‘Standard clinical care pathway’. The
PAM is a well-validated generic measure of patient activa-
tion that evaluates the knowledge, skills, beliefs and
behaviours that patients have for self-management of
their long-term condition.45 46 It has been used exten-
sively in over 200 peer-reviewed published studies.47 The
SSQ is a 49-item questionnaire measuring self-reported
hearing disability over three domains: difﬁculties under-
standing speech in different situations, localising and
tracking sounds, and ease of listening and naturalness of
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sound.48 The HUI mark 3 (HUI3) is a multiattribute
health status classiﬁcation system evaluating eight
domains of vision, hearing, speech, ambulation, dexter-
ity, emotion, cognition and pain.49
The following information will be collected on the
control group and remote care group during the clinical
trial:
▸ Number and nature of clinic contacts and visits
(including non-attendance);
▸ Repair logs;
▸ Age;
▸ Gender;
▸ Postcode (to calculate distance to clinic)—postcode
data will be used once only in order to calculate the
distance to the clinic and will then be destroyed;
▸ Cochlear implant device and speech processor;
▸ Highest formal educational qualiﬁcations;
▸ Which cochlear implant centre takes care of the
participant.
All staff will be reminded to document all contact with
patients as usual. Additionally in the remote care group,
logs of their interaction with the remote care tools will
be stored to assess adherence and utility.
Exit measures (summer 2016)
All participants will undergo the following exit
measures:
▸ Speech recognition testing (BKB sentences in quiet
and noise and TDT);
▸ PAM;
▸ SSQ questionnaire;
▸ HUI3.
Travel expenses will be paid for baseline and exit
measure visits. The day of the exit measures will be con-
sidered to be the day the participants exit from the trial.
Participants in the remote care group will be asked to
attend a focus group on the day of their exit measures
in order to collect qualitative preference and experience
data. Focus groups will be audio recorded and tran-
scribed. A small number of participants in the remote
care group will be asked if they would be willing to be
videoed talking about remote care. These videos will be
stored securely on a University of Southampton
password-protected network using just the participant’s
ID. They will be used in presentations to report and
promote the research.
Primary outcome measure
▸ Change (from day of entry into study to 6 months
after remote care introduced) in patient activation
measured using the PAM.
Secondary outcome measures
▸ Stability of hearing measured by change (from day of
entry into study to 6 months after remote care intro-
duced) in speech recognition measured using BKB
sentences, the TDT, the SSQ questionnaire in the
control and treatment arms.
▸ Stability of quality of life measured by change (from
day of entry into study to 6 months after remote care
introduced) in quality of life measured using the
HUI3 in the control and treatment arms.
▸ Patient preference for and experience of remote care
in treatment arm reported qualitatively from feedback
in online support tool and focus groups.
▸ Clinician preference for and experience of remote
care measured qualitatively from three interviews with
up to 10 members of clinical staff.
Feasibility outcomes
▸ Recruitment (number of eligible and willing
participants);
▸ Attrition (drop-out) and bias;
▸ Adherence to protocol;
▸ Acceptability of randomisation to service users;
▸ Willingness and ability to use remote care tools
(hearing test, Remote Assistant Fitting, online
support tool).
Hypotheses
Primary
▸ The remote care group will show a greater increase
in patient engagement over the 6-month remote care
trial period than the control group, measured using
the PAM.
Secondary
▸ There will be no more deterioration in hearing in the
remote care group compared with the control group,
measured using speech recognition (BKB, TDT) and
the SSQ questionnaire.
▸ There will be no more deterioration in quality of life
in the remote care group compared with the control
group, measured using the HUI3.
▸ Service users (patients) will feel positive about
remote care, measured qualitatively from feedback in
online support tool and in focus groups.
▸ Clinicians will feel positive about remote care, mea-
sured qualitatively from interviews with clinical staff.
Data handling
Data will be managed according to the University of
Southampton Research Data Management Policy
(RDMP). An individual study data management plan is
stored on the University network. Stored data will be
coded and anonymised, will not include name or
address information and will be stored securely: all elec-
tronic data will be password protected. Hard copy data
will be stored in a locked ﬁling cabinet in a secure
ofﬁce. The University provides secure storage for all
active research data (http://library.soton.ac.uk/
researchdata/unistorage). The data are regularly backed
up and a copy of the backup is regularly off-sited to a
secure location for disaster recovery purposes. Research
data will be kept for at least 10 years in line with
University of Southampton policy.
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Metadata records for the data (and published
outputs) will also be maintained on the University of
Southampton Institutional Research Repository
(ePrints). Each deposit can be assigned a unique digital
object identiﬁer via the DataCite scheme, allowing it to
be cited in publications. No personal data or identiﬁable
data will be included in the data stored in the repository.
This will be in accordance with the University’s data
security policy (http://www.calendar.soton.ac.uk/
sectionIV/dppolicy.pdf) and the requirements of the
Data Protection Act (1998).
The terms of the PAM licence specify that up to 250
participants can be tested until August 2016.
Non-personally identiﬁable individual data must be
shared with Insignia. The data shared shall include
individual-level data records containing answers to each
of the PAM questions, and if captured (1) demographic
variables, health status and condition variables; (2) spe-
ciﬁc outcome variables including health behaviours, self-
management behaviours and whether patients using
PAM improved the self-management aspects of their
healthcare and (3) the PAM materials’ effect on or rela-
tionship to patient healthcare utilisation and costs. Such
data shall be reported to Insignia in an electronic
format in approximately September 2016.
A data monitoring committee is not required due to
the short period of follow-up and minimal project risks.
Trial organisation and monitoring
The trial is led by the PI (HC). Monthly research team
meetings will be held. We have formed a Steering
Group, with the remit of reﬂecting on the process and
governance of the project including adverse events mon-
itoring. The Steering Group comprises three USAIS clin-
icians, the USAIS Director, the PI, a consultant on
change management (NC) and two service users
(patients). It will meet at least three times.
Data analysis plan
To comply with recommendations, analysis will be mainly
descriptive.50 Scores on the PAM (primary outcome),
quality of life and hearing results will be compared
between the two groups (control and remote care
group), although statistical analysis of any differences will
be interpreted with caution as no formal power calcula-
tion was in place, and will primarily be used to estimate
effect sizes. Analysis will focus on whether the generic
PAM is sensitive enough to show change, or whether a
condition-speciﬁc empowerment measure needs to be
developed. Clinician and participant feedback, use of
clinic resources (number and type of appointments) and
feasibility outcomes will be reported and analysed quali-
tatively. IBM SPSS Statistics V.21 will be used.
Public and patient involvement
The research team has a strong commitment to public
and patient involvement (PPI); a member of the
research team is a service user. This service user was
known to the PI to be interested in remote care, and
has served on the USAIS Governance Group. The
research team contains representatives from the main
stakeholders: patient, clinician, cochlear implant
company. Two additional service users are on the project
Steering Group. Local and national publicity (website,
twitter, presentation to National Cochlear Implant
Users’ Association, newsletter articles, letters, emails,
Yahoo group) have already invited help in designing the
research.
Ethics
Participation is entirely voluntary and it has been
stressed to patients that if they do not participate, this
will not affect their usual clinical care in any way.
Written informed consent will be taken from all partici-
pants by the PI who has regular Good Clinical Practice
(GCP) training. Participants are free to withdraw at any
point without giving a reason. A risk analysis has been
approved by the University of Southampton.
The PI will inform participants during the trial if any
new information comes to light which may affect their
willingness to participate.
Confidentiality
Linked anonymity will be used. Participants will be
assigned a unique identiﬁer on enrolment. All results
will be stored using only this ID. The lookup table will
be stored on a password-protected University of
Southampton network in a password-protected ﬁle sep-
arate from the study results, and will be accessible only
to the research team.
Adults with cochlear implants are still rare in the
general population (∼0.01% of the UK population).
BMJ reporting guidelines will be followed: we will not
report three or more indirect identiﬁers (eg, place of
treatment, sex, rare disease or treatment, age) for any
individuals.51
Dissemination
Research results will be presented locally, nationally and
internationally. Dissemination will include but not be
limited to peer-reviewed research publications both
online and in print, conference and meeting presenta-
tions, posters, newsletter articles, website reports, and
social media. In order to inform people with cochlear
implants of the results, information will be sent to the
National Cochlear Implant Users’ Association and other
patient groups, and the USAIS patient newsletter.
Participants will be offered the opportunity to receive a
summary of the ﬁndings.
CONCLUSION
This will be the ﬁrst RCT of a triple approach to remote
care for people using cochlear implants. The study
results will inform further work on a larger scale roll out
of cochlear implant remote care in the UK.
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